Wells Fargo’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Wells Fargo’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4	Closed	–	–	7285
2019 Q4	$0	Sell	4 -3	-43%	-$7	﹤0.01%	6985
2019 Q3	$0	Sell	7 -509	-99%	-$1.83K	﹤0.01%	6944
2019 Q2	$4K	Sell	516 -3,293	-86%	-$12.5K	﹤0.01%	6093
2019 Q1	$13K	Sell	3,809 -97	-2%	-$526	﹤0.01%	5604
2018 Q4	$16K	Sell	3,906 -1,762	-31%	-$22.5K	﹤0.01%	5831
2018 Q3	$113K	Buy	5,668 +819	+17%	+$20.7K	﹤0.01%	5308
2018 Q2	$155K	Buy	4,849 +3,653	+305%	+$132K	﹤0.01%	5164
2018 Q1	$45K	Sell	1,196 -362	-23%	-$23.8K	﹤0.01%	5605
2017 Q4	$123K	Buy	+1,558	New	+$115K	﹤0.01%	5218

Wells Fargo's MLNT Position: Q1 2020 in Review

Wells Fargo sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 4 shares.

Wells Fargo first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $155K in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Wells Fargo reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Wells Fargo sold 4 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
Wells Fargo first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Wells Fargo's Melinta Therapeutics, Inc. Common Stock position peaked at $155K in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Wells Fargo's 13F filing for Q1 2020, filed 14 May 2020.